MEREO BIOPHARMA GROUP PLC

(MREO)
  Report
Delayed Nasdaq  -  09:31 2022-08-10 am EDT
1.170 USD    0.00%
08/08European ADRs Move Higher in Monday Trading
MT
08/05European ADRs Move Lower in Friday Trading
MT
08/01European ADRs Move Higher in Monday Trading
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
1.18(c) 1.29(c) 1.18(c) 1.17(c) 1.17 Last
1 078 111 1 455 588 1 884 863 1 215 870 27 174 Volume
+3.51% +9.32% -8.53% -0.85% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2022 - - -
Net income 2022 -39,7 M -47,9 M -47,9 M
Net cash position 2022 32,5 M 39,3 M 39,3 M
P/E ratio 2022 -13,2x
Yield 2022 -
Sales 2023 12,2 M 14,7 M 14,7 M
Net income 2023 -29,6 M -35,8 M -35,8 M
Net cash position 2023 7,80 M 9,43 M 9,43 M
P/E ratio 2023 -16,1x
Yield 2023 -
Capitalization 105 M 127 M 127 M
EV / Sales 2022 -
EV / Sales 2023 8,00x
Nbr of Employees 49
Free-Float 51,6%
More Financials
Company
Mereo BioPharma Group plc is a United Kingdom-based biopharmaceutical company. The Company is focused on the development of therapeutics that aim to improve outcomes for oncology and rare diseases and focuses on commercializing selected rare disease programs. Its portfolio consists of six clinical-stage product candidates two of which, Etigilimab (MPH-313) and Alvelestat (MPH-966), are in ongoing clinical studies.... 
More about the company
All news about MEREO BIOPHARMA GROUP PLC
08/08European ADRs Move Higher in Monday Trading
MT
08/05European ADRs Move Lower in Friday Trading
MT
08/01European ADRs Move Higher in Monday Trading
MT
07/29European ADRs Move Higher in Friday Trading
MT
07/27European ADRs Move Higher in Wednesday Trading
MT
07/25European ADRs Move Higher in Monday Trading
MT
07/21European ADRs Nudge Higher in Thursday Trading
MT
07/20European ADRs Move Lower in Wednesday Trading
MT
07/19European ADRs Rise in Tuesday Trading
MT
07/12European ADRs Move Lower in Tuesday Trading
MT
07/08European ADRs Move Slightly Higher in Friday Trading
MT
07/05MEREO BIOPHARMA : Regains Compliance with Nasdaq Minimum Bid Price Requirement - Form 6-K
PU
07/05Mereo BioPharma Regains Compliance With Nasdaq Minimum Bid Price
MT
07/05Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
AQ
07/01European ADRs Fall Sharply in Friday Trading
MT
More news
News in other languages on MEREO BIOPHARMA GROUP PLC
08/08Les ADR européens progressent lundi
08/05Les ADR européens sont en baisse vendredi
08/01Les ADR européens progressent lundi
07/29Les ADR européens sont en hausse vendredi
07/27Les ADR européens sont en hausse mercredi
More news
Analyst Recommendations on MEREO BIOPHARMA GROUP PLC
More recommendations
Chart MEREO BIOPHARMA GROUP PLC
Duration : Period :
Mereo BioPharma Group plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEREO BIOPHARMA GROUP PLC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 96,80 GBX
Average target price 562,57 GBX
Spread / Average Target 481%
EPS Revisions
Managers and Directors
Denise Vera Scots-Knight Chief Executive Officer & Director
Christine Fox Chief Financial Officer
Michael S. Wyzga Chairman
John A. Lewicki Chief Scientific Officer
Suba Krishnan Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
MEREO BIOPHARMA GROUP PLC-26.88%127
GILEAD SCIENCES, INC.-14.61%77 266
VERTEX PHARMACEUTICALS36.08%75 386
REGENERON PHARMACEUTICALS, INC.-1.48%67 420
BIONTECH SE-39.02%41 143
WUXI APPTEC CO., LTD.-20.94%40 375